Eli Lilly and Company (NYSE:LLY) Shares Purchased by Aviso Wealth Management

Aviso Wealth Management boosted its stake in Eli Lilly and Company (NYSE:LLY) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,080 shares of the company’s stock after purchasing an additional 66 shares during the quarter. Aviso Wealth Management’s holdings in Eli Lilly and Company were worth $1,606,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Principal Financial Group Inc. grew its holdings in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after purchasing an additional 60,306 shares during the period. Penserra Capital Management LLC increased its holdings in Eli Lilly and Company by 45.2% in the 3rd quarter. Penserra Capital Management LLC now owns 870 shares of the company’s stock valued at $770,000 after purchasing an additional 271 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Eli Lilly and Company by 24.7% in the third quarter. Loomis Sayles & Co. L P now owns 1,869 shares of the company’s stock valued at $1,656,000 after buying an additional 370 shares in the last quarter. Truvestments Capital LLC raised its holdings in shares of Eli Lilly and Company by 36.1% during the 3rd quarter. Truvestments Capital LLC now owns 565 shares of the company’s stock valued at $500,000 after buying an additional 150 shares during the period. Finally, Qsemble Capital Management LP purchased a new position in Eli Lilly and Company in the 3rd quarter worth approximately $2,899,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $852.35 on Wednesday. The company has a market cap of $808.17 billion, a P/E ratio of 72.79, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The business’s fifty day moving average is $839.56 and its 200-day moving average is $837.61. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has authorized a stock repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Citigroup reduced their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.